CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OMGA
351
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $2.79K | ﹤0.01% |
488
+40
| +9% | +$228 |
|
352
Phibro Animal Health
PAHC
$1.49B
| $2.78K | ﹤0.01% |
207
+17
| +9% | +$228 |
|
|
KNTE
353
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.73K | ﹤0.01% |
448
+34
| +8% | +$207 |
|
354
Foghorn Therapeutics
FHTX
$298M
| $2.71K | ﹤0.01% |
+425
| New | +$2.71K |
|
|
PETQ
355
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $2.71K | ﹤0.01% |
294
+19
| +7% | +$175 |
|
356
Starbucks
SBUX
$102B
| $2.58K | ﹤0.01% |
26
-2,800
| -99% | -$278K |
|
357
Biomea Fusion
BMEA
$121M
| $2.51K | ﹤0.01% |
298
+23
| +8% | +$194 |
|
358
Annexon
ANNX
$227M
| $2.5K | ﹤0.01% |
484
+38
| +9% | +$196 |
|
359
PayPal
PYPL
$66.2B
| $2.42K | ﹤0.01% |
34
| – | – |
|
360
Generation Bio
GBIO
$40.3M
| $2.37K | ﹤0.01% |
604
+52
| +9% | +$204 |
|
|
IMAB
361
I-MAB
IMAB
$357M
| $2.31K | ﹤0.01% |
553
+56
| +11% | +$234 |
|
362
Nautilus Biotechnolgy
NAUT
$85M
| $2.28K | ﹤0.01% |
1,267
+99
| +8% | +$178 |
|
363
Acumen Pharmaceuticals
ABOS
$82.4M
| $2.25K | ﹤0.01% |
416
+37
| +10% | +$200 |
|
364
Prelude Therapeutics
PRLD
$64M
| $2.24K | ﹤0.01% |
370
-78
| -17% | -$471 |
|
365
Quantum-Si Incorporated
QSI
$219M
| $2.23K | ﹤0.01% |
1,218
+99
| +9% | +$181 |
|
366
Humacyte
HUMA
$239M
| $2.21K | ﹤0.01% |
1,047
+82
| +8% | +$173 |
|
367
Ocular Therapeutix
OCUL
$2.21B
| $2.2K | ﹤0.01% |
782
+61
| +8% | +$171 |
|
|
ADAP
368
Adaptimmune Therapeutics
ADAP
$15.3M
| $2.15K | ﹤0.01% |
1,469
+124
| +9% | +$181 |
|
369
Gossamer Bio
GOSS
$589M
| $2.08K | ﹤0.01% |
960
+80
| +9% | +$174 |
|
370
UroGen Pharma
URGN
$904M
| $2.08K | ﹤0.01% |
234
+21
| +10% | +$186 |
|
|
OPTN
371
DELISTED
OptiNose
OPTN
| $2.07K | ﹤0.01% |
1,116
+336
| +43% | +$622 |
|
372
Absci
ABSI
$350M
| $1.97K | ﹤0.01% |
939
+70
| +8% | +$147 |
|
|
LENZ
373
LENZ Therapeutics
LENZ
$1.12B
| $1.96K | ﹤0.01% |
591
+45
| +8% | +$149 |
|
|
EXAI
374
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $1.96K | ﹤0.01% |
+367
| New | +$1.96K |
|
|
MRNS
375
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.93K | ﹤0.01% |
485
+136
| +39% | +$541 |
|